AIM
CNCE

Acrospire Investment Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Acrospire Investment Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,812
Closed -$32K – 2218
2016
Q2 		$32K Sell
2,812
-4,300
-60% -$54.8K 0.02% 1355
2016
Q1 		$97K Buy
+7,112
New +$102K 0.07% 343

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acrospire Investment Management's CNCE Position: Q3 2016 in Review

Acrospire Investment Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2016, closing a stake of 2,812 shares — an estimated $32K sold.

Acrospire Investment Management first reported a position in CNCE in Q1 2016 and held it in 2 quarters. The position peaked at $97K in Q1 2016. 94 funds tracked by Wall St. Rank hold CNCE as of Q3 2016.

  • Acrospire Investment Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 2,812 Concert Pharmaceuticals, Inc. shares in Q3 2016, an estimated $32K.
  • Acrospire Investment Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Concert Pharmaceuticals, Inc. position peaked at $97K in Q1 2016.
  • 94 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2016.

Based on Acrospire Investment Management's 13F filing for Q3 2016, filed 10 Nov 2016.